Top Stories
The Australian company's AI model aims to generate predictive risk scores for heart failure using echocardiographic data.
Clairyon's COMPOSER model will draw on SEQSTER's patient records, lab results, genomics and wearable data to spot sepsis before patients are already in danger.
Guardant360 CDx can now be used as a blood-based companion diagnostic for Boehringer Ingelheim's Hernexeos, a targeted treatment for HER2-mutant advanced NSCLC.
The venture capital firm is targeting early and growth-stage companies focused on interventional therapies, diagnostics, monitoring and the digitalisation of healthcare.
The new system can identify more than 100 molecular subtypes of central nervous system tumours using standard tissue sections.
Conference News
HerResolve™ demonstrated strong diagnostic performance and the ability to identify endometriosis cases missed by imagingBOSTON, MA, UNITED STATES, June 15, 2026 /EINPresswire.com/ -- HerAnova™ Lifesci...
New non-invasive prenatal testing technique gives results comparable to invasive methods, with advantages in both safety and cost | EurekAlert! ...
Model recommended selective screening of patients with high blood pressure for primary aldosteronismReports and ProceedingsThe Endocrine SocietyChicago—A study of a new AI model examining 30 years of ...
GOTHENBURG, Sweden, June 13, 2026 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company committed to developing core tools and technologies that drive innovation in life sciences, is showcasing its late...
RIYADH, Saudi Arabia, June 14, 2026 (GLOBE NEWSWIRE) -- At HLTH Europe 2026 in Amsterdam, taking place from June 15 to 18, King Faisal Specialist Hospital & Research Centre (KFSH) will highlight that ...
